Contemporary trends in utilization and outcomes of percutaneous left atrial appendage occlusion in the United States from 2016 to 2019

Published:October 14, 2022DOI:
      Atrial fibrillation is a major cause of stroke and thromboembolism, and oral anticoagulation is the mainstay of prevention. In patients who are poor candidates for long-term anticoagulation, percutaneous left atrial appendage occlusion (pLAAO) emerged as an alternative stroke prevention strategy and was approved by the US Food and Drug Administration in 2015. We aimed to examine trends in procedural volume, resource utilization, and clinical outcomes of pLAAO from a nationally representative cohort.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Agency for Healthcare Research and Quality
        Healthcare Cost & Utilization Project User Support. Overview of the National (Nationwide) Inpatient Sample (NIS).
        Date accessed: June 30, 2022
      1. U.S. Bureau of Labor Statistics. CPI Inflation Calculator. Accessed June 30, 2022.

        • Holmes D.R.
        • Reddy V.Y.
        • Turi Z.G.
        • et al.
        Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial.
        Lancet. 2009; 374: 534-542
        • Holmes D.R.
        • Kar S.
        • Price M.J.
        • et al.
        Prospective randomized evaluation of the Watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial.
        J Am Coll Cardiol. 2014; 64: 1-12
        • Freeman J.V.
        • Varosy P.
        • Price M.J.
        • et al.
        The NCDR Left Atrial Appendage Occlusion Registry.
        J Am Coll Cardiol. 2020; 75: 1503-1518